Last 4,870 GBp
Change Today +270.00 / 5.87%
Volume 3.2M
SHP On Other Exchanges
Symbol
Exchange
SHP is not on other exchanges.
As of 11:45 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

shire plc (SHP) Snapshot

Open
4,596 GBp
Previous Close
4,600 GBp
Day High
4,870 GBp
Day Low
4,577 GBp
52 Week High
07/8/14 - 4,925 GBp
52 Week Low
07/25/13 - 2,175 GBp
Market Cap
28.7B
Average Volume 10 Days
3.5M
EPS TTM
2.39 GBp
Shares Outstanding
589.3M
EX-Date
03/5/14
P/E TM
34.9x
Dividend
12.16 GBp
Dividend Yield
0.25%
Current Stock Chart for SHIRE PLC (SHP)

shire plc (SHP) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.

5,338 Employees
Last Reported Date: 02/24/14
Founded in 1986

shire plc (SHP) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $2.7M
Compensation as of Fiscal Year 2013.

shire plc (SHP) Key Developments

U.S. District Court Finds Patents for Shire's Vyvanse ADHD Treatment were Infringed, Valid

Shire announced that judge of the U.S. District Court for the District of New Jersey granted company's summary judgment motion in a patent-infringement lawsuit, holding that certain claims of the patents protecting its Vyvanse (lisdexamfetamine dimesylate) Attention-Deficit/Hyperactivity Disorder treatment were both infringed and valid. The court's summary judgment ruling included 18 patent claims from four of the Food and Drug Administration Orange Book-listed patents for Vyvanse, which cover Vyvanse's active ingredient--the lisdexamfetamine dimesylate compound--and a method of using lisdexamfetamine dimesylate for the treatment of ADHD. The ruling prevents the five pharmaceutical manufacturers who had filed Abbreviated New Drug Applications from launching generic versions of Vyvanse until the earlier of either a successful appeal to the U.S. Court of Appeals for the Federal Circuit, or the expiration of these patents in 2023. To appeal successfully, the ANDA defendants would have to overturn the court's rulings for each of the 18 patent claims. The court's rulings denied API supplier Johnson Matthey's motion to dismiss certain indirect infringement claims, dismissed shire's willful-infringement claims, granted defendants' motion concerning noninfringement of certain method of use claims, and denied defendants' two invalidity motions.

AbbVie Inc., Shire plc - M&A Call

To discuss the indicative merger proposal

Shire Provides Sales Guidance for the Years 2020 and 2016

Shire provided sales guidance for the year 2020. For 2020, it expects its product sales to double by 2020 and amount to USD 10 billion. By 2016, the company expects its product sales to reach USD 6.5 billion. Specifically, of the USD 10 billion, USD 7 billion is to come from in-line product sales, and USD 3 billion is to come from the existing pipeline products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHP:LN 4,870.00 GBp +270.00

SHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $217.65 USD +1.13
Allergan Inc/United States $166.43 USD +0.83
Celgene Corp $89.19 USD +1.36
CSL Ltd A$67.49 AUD +0.03
Valeant Pharmaceuticals International Inc C$129.19 CAD +0.84
View Industry Companies
 

Industry Analysis

SHP

Industry Average

Valuation SHP Industry Range
Price/Earnings 33.4x
Price/Sales 9.0x
Price/Book 8.2x
Price/Cash Flow 55.9x
TEV/Sales 9.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.